Search

everythinglearnresearchcommunity

for

Search:↓

PP405, a topical LDH inhibitor, has shown to stimulate hair follicle stem cell proliferation in humans with moderate hair loss. They are advancing to more detailed trials this year.

The conversation is about using distilled water as a solvent for topical finasteride to reduce systemic absorption. The user is considering avoiding ethanol and propylene glycol to achieve this.

Kirkland Minoxidil typically contains 50-60% propylene glycol. Users suggest adjusting the percentage for sensitive skin.

Selling KY19382 powder, a novel activator of Wnt/β-catenin signaling, and Kolliphor EL liquid for vehicle formulation. KY19382 is a growth agonist.

Pelage is delaying the start of phase 3 trials for PP405 to 2026 due to necessary regulatory processes, despite having $120 million in funding. Users discuss the potential of PP405 for hair regrowth, with some expressing skepticism and others hopeful for new treatments like Breezula.

PP405 is a topical gel being tested for hair regrowth in adults with androgenetic alopecia. Volunteers aged 18-55 are needed for a 16-week trial in several US locations.

The conversation is about finding a place to buy 0.025% topical finasteride in liposomal gel form in Europe. The user previously mixed their own with stemoxydine but stopped due to an oily scalp.

The conversation discusses hair loss treatments, mentioning minoxidil, finasteride, RU58841, VDPHL, GT20029, and follicle cloning as potential solutions. It also reveals that the discussion about PP405 was an April Fool's joke.

The conversation is about the stability of pyrilutamide in different solutions. The user is asking if a 70/30 ethanol/pg solution with 4% water will degrade pyrilutamide.

The conversation is about selling KY19382 powder, a novel activator of Wnt/β-catenin signaling, and Kolliphor EL liquid for vehicle formulation. The seller offers worldwide shipping.

A user is experiencing scalp flaking from a finasteride/minoxidil topical solution and considers using salicylic acid shampoo to remove propylene glycol residue. Another user suggests trying a leave-in conditioner to address dryness and flaking.

PP405 is a promising molecule that may reactivate dormant hair follicles, potentially offering a new treatment for hair loss. It is in phase 2 trials, with possible availability between 2027 and 2030.

Excess sebum rich in cholesterol and triglycerides can lead to hair loss through inflammation, with treatments like Ciclopirox shampoo, Benzoyl Peroxide shampoo, and Clindamycin gel recommended for managing conditions like seborrheic dermatitis and folliculitis. Pioglitazone is suggested for Lichen Planopilaris, while Omega-3s and reducing processed foods may improve sebum quality, though genetic factors play a significant role.

Pelage Pharmaceuticals raised $120M for their hair loss treatment, PP405, showing strong investor confidence despite limited data. There is skepticism about its efficacy and long-term effects compared to treatments like GT20029.

A user is considering adding PRP and mesotherapy to their hair loss treatment and is deciding between two options: Promoitalia, which contains Phosphatidic acid, Riboflavin, and Superoxide dismutase, and the more expensive Melsmon, a human placenta derivative. They seek advice on which option to choose based on effectiveness and scientific backing.

The user is looking for a PG-free solvent in the UK or EU to make their own pyrilutamide solution for hair loss and is currently using finasteride, considering minoxidil. They hope pyrilutamide will help stabilize their hair loss.

PP405 is a potential hair loss treatment that inhibits mitochondrial pyruvate carriers, increasing lactate dehydrogenase activity and stimulating hair follicle stem cells. In a phase 1 trial, 31% of participants showed over 20% hair density increase with PP405 treatment.

Prostaglandin balance affects hair loss, particularly in conditions like Lichen Planopilaris, where an imbalance can lead to hair follicle damage. Treatments mentioned include prostaglandin analogs and Pioglitazone HCL, with a focus on maintaining prostaglandin equilibrium for potential hair regrowth.

Liposomal carriers for topical finasteride offer better targeting, reduced side effects, and less irritation compared to alcohol-based solutions, but availability and cost may limit their use. Minoxidil can dissolve in liposomal carriers, enhancing delivery and stability.

Folligenz liposomal minoxidil sulfate is being discussed for its effectiveness and cost, with users comparing it to regular minoxidil and tretinoin. One user found no difference with the 10% version and noted that a lower tretinoin percentage reduced side effects like skin peeling.

The conversation discusses using propanediol as an alternative to glycerin in PG-free minoxidil for better absorption. The user also plans to try nanoxidil, which may absorb more easily due to its smaller molecule size.

Pelage Pharmaceuticals received $120 million in Series B funding for hair loss treatment development. The conversation expresses excitement and anticipation for the release and effectiveness of the treatment.

PP405, a potential hair loss treatment, is facing delays in releasing Phase 2 results, causing frustration among users who compare it to past failed treatments. Despite skepticism, some remain hopeful about PP405's future, while others discuss alternative treatments like Clascoterone and its expected market release.

The user discusses a galenic hair lotion containing progesterone, estradiol, cyproterone, hydrocortisone butyrate, and cetirizine pheniramine, which has effectively stopped their hair loss over two years. They are curious about the compatibility of finasteride with the lotion's components and note that their trichologist has successfully used minoxidil and finasteride in similar treatments for others.

A 34 year old female with androgenic alopecia who has tried treatments such as Spironolactone, Desogen, Minoxidil and Finasteride in order to address her hair loss. It also details the experiences of other women taking Spironolactone for Female Pattern Hair Loss (FPHL).

User uses 1ml RU58841 with 5ml stemoxydine for scalp coverage. Wants to switch to pyrilutamide and asks about mixing it with other compounds.

PP405 is a potential hair loss treatment showing promise, especially for men with severe balding. Some are hopeful it will be a game-changer for those who cannot tolerate finasteride or minoxidil, despite skepticism about the outcomes.

The conversation is about a female seeking advice on using bicalutamide for female pattern hair loss (FPHL) and considering switching from pumpkin seed oil pills to a stronger treatment. She is looking for dosage information to discuss with her dermatologist.

The conversation is about using liposomal finasteride for hair loss treatment, highlighting its cost-effectiveness and ease of preparation. It suggests using lecithin and crushed finasteride pills to make the solution, which has shown to be significantly more effective than other topical formulations.

Bicalutamide and spironolactone are being compared for their effectiveness and safety in treating female pattern hair loss. The conversation seeks advice on which is better to use.